Editors
Giampaolo Tortora
Medical Oncology and Comprehensive Cancer Center, University and Hospital Trust, Verona, Italy
Cristiana Sessa
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Aldo Scarpa
ARC-Net Research Centre, University and Hospital Trust of Verona, Verona; Department of Pathology and Diagnostics, University and Hospital Trust of Verona, Verona, Italy
Susana Banerjee
The Royal Marsden Hospital, London and Surrey, UK
Contributors
Chapter 1 - Definition: Translational and Personalised Medicine, Biomarkers, Pharmacodynamics
R.C. Pezo - Princess Margaret Cancer Centre, Toronto, Canada
P.L. Bedard - Princess Margaret Cancer Centre, Toronto, Canada
Chapter 2 - Biology of Normal and Tumour Cells (Self-sufficiency and Insensitivity to Anti-proliferative Signals, Apoptosis, Limitless Replicative Potential)
A. Capasso* - Developmental Therapeutics/Phase I Program, Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora, CO, USA
K.M. Wong* - Developmental Therapeutics/Phase I Program, Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora, CO, USA
S.G. Eckhardt - Developmental Therapeutics/Phase I Program, Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora, CO, USA
*co-first authorsChapter 3 - Principles of Tumour Immunology and Immunotherapy
S. Höpner - Tumor Immunology, Department of Clinical Research, University of Bern, Bern, Switzerland
C. Riether - Tumor Immunology, Department of Clinical Research, University of Bern, Bern, Switzerland
A.F. Ochsenbein - Tumor Immunology, Department of Clinical Research, University of Bern, Bern, Switzerland; Department of Medical Oncology, Inselspital, University Hospital and University of Bern, Bern, Switzerland
Chapter 4 - Classes of Drugs and Mechanisms of Action
M. Joerger - Department of Medical Oncology & Hematology, Cantonal Hospital, St. Gallen, Switzerland
G.J. Peters - Department of Medical Oncology, VU University Medical Centre, Amsterdam, The Netherlands. On behalf of the Pharmacology & Molecular Mechanisms Group (PAMM) of the European Organisation for Research and Treatment of Cancer (EORTC)
Chapter 5 - Techniques and New Diagnostic Technologies (Limitations, Applications)
A. Scarpa - ARC-Net Research Centre, University and Hospital Trust of Verona, Verona; Department of Pathology and Diagnostics, University and Hospital Trust of Verona, Verona, Italy
M. Simbolo - ARC-Net Research Centre, University and Hospital Trust of Verona, Verona, Italy
F. Fenizia - Laboratory of Pharmacogenomics, Centro di Ricerche Oncologiche di Mercogliano (CROM) – Istituto Nazionale Tumori “Fondazione Giovanni Pascale” IRCCS, Napoli, Italy
N. Normanno - Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori “Fondazione Giovanni Pascale” IRCCS, Napoli, Italy
Chapter 6 - Angiogenesis and Metastasis
C.B. Wyss - Laboratory of Experimental and Translational Oncology, Division of Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Switzerland
G. Lorusso - Laboratory of Experimental and Translational Oncology, Division of Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Switzerland
C. Rüegg - Laboratory of Experimental and Translational Oncology, Division of Pathology, Department of Medicine, Faculty of Science, University of Fribourg, Switzerland
Chapter 7 - Mutations, Genomic Instability, and Cancer Evolution
M. Ashenden* - Translational Oncogenomics Laboratory, Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK
K. Khan* - Translational Oncogenomics Laboratory, Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK; GI Cancer Unit, The Royal Marsden Hospital, London, UK
L.J. Barber - Translational Oncogenomics Laboratory, Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK
M. Gerlinger - Translational Oncogenomics Laboratory, Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK; GI Cancer Unit, The Royal Marsden Hospital, London, UK
*co-first authorsChapter 8 - Avoiding Immune Destruction-Immunotherapy
K. Homicsko - Department of Oncology, University Hospital of Lausanne, Lausanne, Switzerland
D.E. Speiser - Department of Oncology, University Hospital of Lausanne, Lausanne, Switzerland
O. Michielin - Department of Oncology, University Hospital of Lausanne, Lausanne, Switzerland
Chapter 9 - Tumour-promoting Inflammation
P. Allavena - Clinical and Research Institute Humanitas, Rozzano-Milano, Italy
A. Mantovani - Clinical and Research Institute Humanitas, Rozzano-Milano, Italy; Humanitas University, Rozzano-Milano, Italy
Chapter 10 - Molecular Diagnostics and Biomarkers: Application and Limits
C. Hierro - Medical Oncology Department, Vall d´Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
I. Braña - Medical Oncology Department, Vall d´Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
J. Rodon - Medical Oncology Department, Vall d´Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
J. Tabernero - Medical Oncology Department, Vall d´Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Declarations of Interest
Chapter 1: Dr Pezo has reported no conflicts of interest.
Dr Bedard has reported a consulting or advisory role with Pfizer, Genentech/Roche, and Sanofi, and research funding from Bristol-Myers Squibb, Sanofi, Genentech/Roche, Novartis, SignalChem, Oncothyreon, GlaxoSmithKline, and AstraZeneca.
Chapter 2: Dr Capasso has reported no conflicts of interest.
Dr Wong has reported no conflicts of interest.
Prof Eckhardt has reported no conflicts of interest.
Chapter 3: Dr Höpner has reported no conflicts of interest.
Dr Riether has reported no conflicts of interest.
Prof Ochsenbein has reported no conflicts of interest.
Chapter 4: Dr Joerger has reported no conflicts of interest.
Dr Peters has reported no conflicts of interest.
Chapter 5: Dr Scarpa has reported no conflicts of interest.
Dr Simbolo has reported no conflicts of interest.
Dr Fenizia has reported no conflicts of interest.
Dr Normanno has reported no conflicts of interest.
Chapter 6: Prof Rüegg has declared that he is a founder and stockholder of Diagnoplex and Novigenix.
Dr Wyss has reported no conflicts of interest.
Dr Lorusso has reported no conflicts of interest.
Chapter 7: Dr Ashenden has reported no conflicts of interest.
Dr Khan has reported no conflicts of interest.
Dr Barber has reported no conflicts of interest.
Dr Gerlinger has reported no conflicts of interest.
Chapter 8: Dr Homicsko has reported no conflicts of interest.
Dr Speiser has reported no conflicts of interest.
Dr Michielin has reported no conflicts of interest.
Chapter 9: Dr Allavena has reported no conflicts of interest.
Dr Mantovani has reported no conflicts of interest.
Chapter 10: Dr Hierro has reported no conflicts of interest.
Dr Braña has reported no conflicts of interest.
Dr Rodon has reported an advisory role for Foundation Medicine and Laboratorios Leti.
Prof Tabernero has reported an advisory role for Amgen, Bayer, Chugai, Novartis, Merck-Serono, MSD, Roche, and Taiho.
